''One size fits all'' unique drug to eradicate multiple viral species simultaneously from the central nervous system of co-infected individuals

Projektinformationen

NOVIRUSES2BRAIN

ID Finanzhilfevereinbarung: 828774

DOI

10.3030/828774

Projekt abgeschlossen

EK-Unterschriftsdatum 17 Dezember 2018

Startdatum 1 September 2019

Enddatum 31 August 2025

Finanziert unter

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Gesamtkosten

€ 3 933 965,63

EU-Beitrag

€ 3 933 965,63

Koordiniert durch

FUNDACAO GIMM - GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE
Portugal

CORDIS bietet Links zu öffentlichen Ergebnissen und Veröffentlichungen von HORIZONT-Projekten.

Links zu Ergebnissen und Veröffentlichungen von RP7-Projekten sowie Links zu einigen Typen spezifischer Ergebnisse wie Datensätzen und Software werden dynamisch von OpenAIRE abgerufen.

Leistungen

Open Research Data Pilot (1)

Data Management Plan

"A Data Management Plan (DMP) will be elaborated including what data the project will generate, whether and how it will be made accessible for verification and re-use, and how it will be curated and preserved. Through this DMP the Consortium can define certain datasets to remain closed according to the principle ""as open as possible, as closed as necessary""."

Websites, patent fillings, videos etc. (1)

Website and project logo

Dedicated website will be launched and a project logo, as the first communication package of the project.

Documents, reports (2)

First technical/scientific review meeting report

The Report will include the draft agenda and the presentations to be delivered during the review meeting with the REAEC

Second technical/scientific review meeting report

The Report will include the draft agenda and the presentations to be delivered during the review meeting with the REAEC

Veröffentlichungen

Peer reviewed articles (5)

A designed cyclic analogue of gomesin has potent activity against Staphylococcus aureus biofilms

Autoren: Dias, Susana Pinto, Sandra Silva-Herdade, Ana S. Cheneval, Olivier Craik, David J Coutinho, Ana Castanho, Miguel A. R. B. Henriques, Sónia T. Veiga, Ana Salomé
Veröffentlicht in: J Antimicrob Chemother., 2022, ISSN 0305-7453
Herausgeber: Oxford University Press
DOI: 10.1093/jac/dkac309

Penetrating the Blood-Brain Barrier with New Peptide-Porphyrin Conjugates Having anti-HIV Activity.

Autoren: Mendonça, Diogo A. Bakker, Mariët Cruz-Oliveira, Christine Neves, Vera Angeles Jiménez, Maria Defaus, Sira Cavaco, Marco Veiga, Ana Salomé Cadima Couto, Carla Iris Castanho, Miguel A. R. B. Andreu, David Todorovski, Toni
Veröffentlicht in: Bioconjugate Chem., 2021, ISSN 1043-1802
Herausgeber: American Chemical Society
DOI: 10.1021/acs.bioconjchem.1c00123

Targeting Zika Virus with New Brain- and Placenta-Crossing Peptide–Porphyrin Conjugates

Autoren: Toni Todorovski ,Diogo A. Mendonça ,Lorena O. Fernandes-Siqueira, Christine Cruz-Oliveira ,Giuseppina Guida 1,Javier Valle 1,Marco Cavaco 2ORCID,Fernanda I. V. Limas 3,Vera Neves 2ORCID,Íris Cadima-Couto 2,Sira Defaus 1,Ana Salomé Veiga 2,Andrea T. Da Poian 3,Miguel A. R. B. Castanho 2 and David Andreu
Veröffentlicht in: Pharmaceutics, 2022, ISSN 1999-4923
Herausgeber: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14040738

Antiviral Peptide-Based Conjugates: State of the Art and Future Perspectives

Autoren: David Andreu; Daniela Kalafatovic; Toni Todorovski
Veröffentlicht in: Pharmaceutics, 2023, ISSN 1999-4923
Herausgeber: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics15020357

Repurposing anti-cancer porphyrin derivative drugs to target SARS-CoV-2 envelope

Autoren: Diogo A. Mendonça, Iris Cadima-Couto, Carolina C. Buga, Zoe A. Arnaut, Fabio A. Schaberle, Luis G. Arnaut, Miguel A.R.B. Castanho, Christine Cruz-Oliveira
Veröffentlicht in: Biomedicine & Pharmacotherapy, Ausgabe 176, 2024, Seite(n) 116768, ISSN 0753-3322
Herausgeber: Elsevier Masson
DOI: 10.1016/j.biopha.2024.116768